Does High Lipoprotein(a) Increase Mortality Risk?

What Is Lipoprotein(a) and Why Does It Matter?

Lipoprotein(a) — commonly abbreviated as Lp(a) — is a lipid particle structurally similar to LDL cholesterol, but with an additional protein called apolipoprotein(a) attached. This structural difference makes it more prone to accumulating in arterial walls and contributing to plaque formation. Importantly, Lp(a) levels are primarily determined by genetics, meaning they remain largely stable throughout life and are not significantly altered by diet or exercise.

Most standard lipid panels do not include Lp(a). As a result, many people with elevated levels are unaware of their increased risk. This is one reason why Lp(a) testing is increasingly recommended as part of a more complete cardiovascular and longevity risk assessment — particularly for individuals with a family history of early heart disease or unexplained cardiovascular events.

For a broader view of which blood markers matter most for long-term health, see our guide to the most complete longevity blood panel.

Does High Lipoprotein(a) Increase Mortality Risk?

Evidence consistently supports that elevated Lp(a) increases the risk of cardiovascular death. Large-scale cohort studies and meta-analyses have found that individuals with Lp(a) levels above approximately 50 mg/dL face a meaningfully higher risk of myocardial infarction, stroke, and cardiovascular mortality compared to those with lower levels. This association holds even after adjusting for LDL cholesterol and other traditional risk factors.

Crucially, the relationship appears to be causal, not just correlational. Mendelian randomisation studies — which use genetic variants to test causality — support the view that Lp(a) directly contributes to atherosclerotic disease rather than simply tracking alongside it. This strengthens the case for treating elevated Lp(a) as an independent risk factor, not merely a secondary finding.

That said, having high Lp(a) does not guarantee a cardiovascular event, and having low Lp(a) does not eliminate risk from other factors. Lp(a) is best understood as one component of a broader risk picture — an important one, but not the whole story. Learn more in our complete guide to longevity.

How Lp(a) Drives Cardiovascular Risk

Lp(a) promotes atherosclerosis through several mechanisms. It deposits cholesterol into arterial walls, promotes inflammation within plaques, and inhibits the breakdown of blood clots — a property linked to its apolipoprotein(a) component, which structurally resembles plasminogen, a clot-dissolving protein. This combination of pro-atherogenic and pro-thrombotic effects explains why elevated Lp(a) is particularly concerning for both heart attack and stroke risk.

In addition, some research suggests that Lp(a) may carry oxidised phospholipids that contribute to vascular inflammation. This inflammatory dimension is relevant to longevity, since chronic low-grade inflammation is one of the central drivers of accelerated ageing and age-related disease. For context on how inflammatory markers fit into a longevity blood panel, see our article on IL-6 as a longevity marker.

Risk from Lp(a) appears to scale with absolute levels. Individuals in the top 20–25% of the population distribution — broadly corresponding to levels above 50 mg/dL or 125 nmol/L — carry meaningfully elevated risk. Those with levels in the very high range (above 100 mg/dL) face a substantially greater burden. However, because measurement units and assay methods vary between labs, results should always be interpreted in the context of the specific test used.

Managing Risk When Lp(a) Is Elevated

Lifestyle changes have limited direct impact

Unlike LDL cholesterol, Lp(a) levels do not respond meaningfully to most dietary or lifestyle interventions. A heart-healthy diet, regular physical activity, and avoiding smoking remain important — not because they lower Lp(a) directly, but because they reduce the overall cardiovascular risk environment in which elevated Lp(a) operates. In practice, managing other modifiable risk factors becomes especially important when Lp(a) cannot itself be easily reduced.

Medications and emerging therapies

Historically, high-dose niacin was used to lower Lp(a), but evidence for clinical benefit has been inconsistent and tolerability is poor. PCSK9 inhibitors — a class of injectable cholesterol-lowering drugs — can reduce Lp(a) levels by 20–30% in some individuals, though this reduction may not be sufficient on its own. More targeted approaches are in development, including antisense oligonucleotides and small interfering RNA therapies specifically designed to suppress Lp(a) production. Early clinical trial data are encouraging, and these therapies may represent the most meaningful treatment advance for high Lp(a) in the near future.

For individuals with confirmed high Lp(a), the most practical current approach is to work with a cardiologist or lipid specialist to aggressively manage all other modifiable cardiovascular risk factors — including LDL (specifically ApoB), blood pressure, blood glucose, inflammation, and body composition — while monitoring for the emergence of Lp(a)-targeted therapies as they reach clinical availability.

Testing: who should check their Lp(a)?

Current guidance from the European Atherosclerosis Society recommends that everyone measure their Lp(a) at least once in adulthood. This is particularly relevant for individuals with a personal or family history of premature cardiovascular disease, recurrent events despite well-controlled LDL, or other unexplained cardiovascular risk. Because Lp(a) is genetically stable, a single measurement is generally sufficient unless there is a clinical reason to retest. Understanding your Lp(a) level allows for more accurate risk stratification and better-informed decisions about the intensity of preventive interventions.

For a fuller understanding of how Lp(a) fits into the broader landscape of cardiovascular risk markers, see our article on what Lipoprotein(a) is and how it works.

References and Resources

The following sources provide reliable information on Lipoprotein(a) and its relationship to cardiovascular mortality risk.

Frequently Asked Questions

Conclusion

Elevated Lipoprotein(a) is a genetically determined, independent cardiovascular risk factor with meaningful evidence linking it to increased mortality — primarily through atherosclerosis, plaque development, and impaired clot resolution. Because standard lipid panels typically miss it, many people at elevated risk remain unaware of this component of their cardiovascular profile.

The practical takeaway is straightforward: measure your Lp(a) at least once. If levels are elevated, focus on aggressively managing every other modifiable risk factor — LDL/ApoB, blood pressure, blood glucose, inflammation, and body composition — and stay informed about targeted Lp(a) therapies as they approach clinical availability. High Lp(a) does not make cardiovascular disease inevitable, but understanding it allows for more intelligent, personalised risk management.